CAMBRIDGE, Mass., July 14, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Frederick W. Ahlholm has been appointed vice president of finance and chief accounting officer, effective June 2, 2014.
Mr. Ahlholm is a senior executive with more than 20 years of experience in directing the financial functions at technology and life science companies. His background includes the management of compliance and reporting requirements for companies registered with the U.S. Securities and Exchange Commission. Previously he was vice president of finance and chief accounting officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. He is a CPA and earned his BBA at the University of Notre Dame.
"I am excited to be joining Minerva Neurosciences at this pivotal time, and am looking forward to working with the rest of the executive team to advance our business strategy targeting a range of unmet needs and highly promising commercial opportunities in neuropsychiatric health in the years ahead," said Mr. Ahlholm.
The news of Mr. Ahlholm's appointment comes on the heels of the pricing of the company's initial public offering on June 30, 2014. Shares began trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014.
"Frederick's extensive experience with life sciences companies and his proven ability to contribute to the growth and success of clinical-stage organizations make him an ideal addition to the senior team at Minerva Neurosciences," said Rogerio Vivaldi, MD, MBA, Minerva president and CEO.
About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc.
Media contact:
Jen Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com
Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com
SOURCE Minerva Neurosciences, Inc.
